PAR 4.76% 20.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-4368

  1. 7,758 Posts.
    lightbulb Created with Sketch. 7023
    You clearly can't or didn't bother to read. I wasn't suggesting a class action coming. We were actually discussions PR's long alluded partnerships finally not just being the surrepticiuous pump of the last 4 years and actually being of substance, given the more overt and formal guidance given and suggesting if they did they not ensue, a class action might ensue on very overt and very public guidance given. If you are intent on arguing perhaps read first.

    No class action is likely coming. A partnership is more likely coming, given FDA clearance, at long last, given the more formal forums and more specific/deliberate form in which the partnership guidance given.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.